Analysis of effector CD4 (OX-40+) and CD8 (CD45RA+ CD27-) T lymphocytes in active multiple sclerosis

Acta Neurologica Scandinavica

Volumn 101, Issue 1, 2000, Pages 57-60

  Hintzen, R Q ^a,c   Pot, K ^b   Paty, D ^a   Oger, J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Effector T cells; Multiple sclerosis; T cell subsets; TNF receptor family

Indexed keywords

CD27 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; MULTIPLE SCLEROSIS; T LYMPHOCYTE;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN SHEATH; T-LYMPHOCYTE SUBSETS;

EID: 0033980671     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2000.00011.x     Document Type: Article

References (19)

1. 1. Hohlfeld R. Biotechnological agents for immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997;120:865-916.
2. 2. Rivera-Quinones C, McGavern D, Schmelzer JD, Hunter SF, Low PA, Rodriguez, M. Absence of neurological deficits following extensive demyelination in a class-I deficient murine model of multiple sclerosis. Nat Med 1998;4(2): 187-93.
3. 3. Jurewicz A, Biddison WE, Antel JP. MHC Class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. J Immunol 1998;160:3056-9.
4. 4. Hintzen RQ, De Jong R, Van Lier RAW. CD27: marker and mediator of T-cell activation. Immunol Today 1994;15: 307-11.
5. + T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. J Neurosc Res 1996;43(1):42-9.
6. 6. Weinberg AD, Wallin JJ, Jones RE et al. Target organspecific up-regulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis. J Immunol 1994;152:4712-21.
7. 7. Weinberg AD, Bourdette DN, Sullivan TJ et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 1996;2(2):183-9.
8. + T cells. J Exp Med 1997;186(9):1407-18.
9. 9. Hintzen RQ, De Jong R, Lens SM, Brouwer M, Baars P, Van Lier Raw. Regulation of CD27 expression on subsets of mature T-lymphocytes. J Immunol 1993;151:2426-35.
10. + T-cell development. Immunol Today 1999;20:177-80.
11. 11. Poser CM, Paty DW, Scheinberg LC et al. New diagnosistic criteria for MS: guidelines for research protocols. Ann Neurol 1983;3:227-31.
12. 12. Lublin FD, Reingold SC. Advisory committee on clinical trials of new agents in multiple sclerosis. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996;46:907-11.
13. 13. McMichael AJ, O'Callaghan CA. A new look at T cells. J Exp Med 1998;187:1367-71.
14. + T cells during the primary immune response to Epstein Barr virus in vitro. J Exp Med 1998;187:1395-402.
15. 15. Murali-Krishna K, Altman JD, Suresh M et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998;8:177-87.
16. 16. Giovannoni G, Kieseier B, Hartung HP. Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:S31-6.
17. 17. Westermann J, Pabst R. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol Today 1990;11:406-10.
18. 18. Rep HG, Schrijver HM, Van Lopik TH et al. Interferonbeta treatment enhances CD95 and interleukin-10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmunol 1999;96:92-100.
19. + T cells with soluble HLA-A2/Tax11 19 tetramer complexes in patients wth human T-cell lymphotropic virus-associated myelopathy. J Immunol 1999;162:1765-71.